宫颈人乳头瘤病毒感染现状及其疫苗的应用现状(4) - 中国疫苗和免疫杂志社投稿

来稿应自觉遵守国家有关著作权法律法规，不得侵犯他人版权或其他权利，如果出现问题作者文责自负，而且本刊将依法追究侵权行为给本刊造成的损失责任。本刊对录用稿有修改、删节权。经本刊通知进行修改的稿件或被采用的稿件，作者必须保证本刊的独立发表权。一、投稿方式： 1、请从我刊官网直接投稿。 2、请从我编辑部编辑的推广链接进入我刊投审稿系统进行投稿。二、稿件著作权： 1、投稿人保证其向我刊所投之作品是其本人或与他人合作创作之成果，或对所投作品拥有合法的著作权，无第三人对其作品提出可成立之权利主张。 2、投稿人保证向我刊所投之稿件，尚未在任何媒体上发表。 3、投稿人保证其作品不含有违反宪法、法律及损害社会公共利益之内容。 4、投稿人向我刊所投之作品不得同时向第三方投送，即不允许一稿多投。 5、投稿人授予我刊享有作品专有使用权的方式包括但不限于：通过网络向公众传播、复制、摘编、表演、播放、展览、发行、摄制电影、电视、录像制品、录制录音制品、制作数字化制品、改编、翻译、注释、编辑，以及出版、许可其他媒体、网站及单位转载、摘编、播放、录制、翻译、注释、编辑、改编、摄制。 6、第5条所述之网络是指通过我刊官网。 7、投稿人委托我刊声明，未经我方许可，任何网站、媒体、组织不得转载、摘编其作品。

宫颈人乳头瘤病毒感染现状及其疫苗的应用现状(4)

作者:

关键词:

摘要：

[24]Matti Lehtinen,JoakimDillner. Clinical trials of human papillomavirus vaccines and beyond[J]. Nature Reviews Clinical Oncology,2013,10(Suppl. 3):84.

[25]Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations[J]. Vaccine,2017,35(43):241-268.

[26]Luxembourg Alain,Moeller Erin. 9-Valent human papillomavirus vaccine: a review of the clinical development program[J]. Expert review of vaccines,2017,16(11):1119-1139.

[27][EB/OL].(2019-09-30)[2020-12-09].

[28][EB/OL].(2019-12-17)[2020-12-09].

[29]Palmer Tim,WallaceLynn,Pollock Kevin G, et al. Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study[J]. BMJ (Clinical research ed.),2019,365:l1161.

[30]Darron R. Brown,Susanne K. Kjaer,Kristján Sigurdsson,et al. The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6,11,16, and 18) L1 Virus-like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Women Aged 16-26 Years[J]. The Journal of Infectious Diseases,2009,199(7):926-935.

[31]Meeting of the Global Advisory Committee on Vaccine Safety,7-8 June 2017[J]. Releveepidemiologique hebdomadai re,2017,92(28):393-402.

[32]de SanjoséSilvia,SerranoBeatriz,Tous Sara, et al. Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58[J]. JNCI cancer spectrum,2018,2(4). :pky045.

[33]Susanne Hartwig,JeanLacau St Guily,GéraldineDominiak-Felden,et al. Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe[J]. Infectious Agents and Cancer,2017,12(1):19.

[34]CastellsaguéXavier,AlemanyLaia,Quer Miquel,et al. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients[J]. Journal of the National Cancer Institute,2016,108(6) :djv403.

[35]Garland Suzanne M,Kjaer Susanne K,Mu?oz Nubia, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience[J]. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,2016,63(4):519-527.

[36]HPV Vaccine Safety and Effectiveness for Disease Control and Prevention.[EB/OL].(2020-06-24)[2020-12-09

[37]ZacharisKonstantinos,Messini Christina I,Anifandis George, et al. Human Papilloma Virus (HPV) and Fertilization: A Mini Review[J]. Medicina (Kaunas, Lithuania),2018,54(4):50.

[38]BondeUlla,Joergensen Jan Stener,Lamont Ronald F,Mogensen Ole. Is HPV vaccination in pregnancy safe?[J]. Human vaccines & immu notherapeutics,2016,12(8):1960-1964.

[39]Elyse O. Kharbanda,Gabriela Vazquez-Benitez,Heather S. Lipkind, et al. Risk of Spontaneous Abortion After Inadvertent Human Papillomavirus Vaccination in Pregnancy[J]. Obstetrics & Gynecology,2018,132(1):35-44.

[40]Wang,Liu,Wang, et al. Pregnancy Outcomes After Human Papillomavirus Vaccination in Periconceptional Period or During Pregnancy: A Systematic Review and Meta-analysis[J]. Human Vaccines & Immunotherapeutics,2020,16(3):581-589.

[41]Safety Information for HPV [EB/OL].[2020-12-09].

[42]D. Maxwell Parkin,Freddie Bray. Chapter 2: The burden of HPVrelated cancers[J]. Vaccine,2006,24 (Suppl 3):S3/11-25.

[43]Laia Bruni,MireiaDiaz,Leslie Barrionuevo-Rosas, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis[J]. The Lancet Global Health,2016,4(7) :e453-63.

[44]Kimberly J. Hassett,Natalie M. Meinerz,FlorianSemmelmann, et al. Development of a highly thermostable, adjuvanted human papillomavirus vaccine[J]. European Journal of Pharmaceutics and Bi opharmaceutics,2015,94:220-228.

[45]RenjieWang,WeiPan,LeiJin, et al. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge[J]. Cancer Letters,2020,471:88-102.

[46]Launch of the Global Strategy to Accelerate the Elimination of Cervical [EB/OL].[2020-12-09].

文章来源：《中国疫苗和免疫》网址: http://www.zgymhmy.cn/qikandaodu/2021/0709/1742.html